US opioid crisis decline reveals systemic failures in harm reduction, not a 'turning point'—rooted in racialized policing, pharmaceutical lobbying, and austerity
Original framing: “[Comment] The US opioid epidemic at a turning point” — The Lancet
Voices of people who use drugs (PWUD), particularly women and racial minorities, are systematically excluded from policy discussions, despite their lived expertise in navigating the crisis. For example, Black women in the South report higher rates of opioid-related deaths due to lack of access to treatment and higher rates of incarceration for drug offenses. Trans and queer communities face additional barriers, such as discrimination in healthcare and housing instability. The ‘turning point’ narrative ignores these disparities, centering instead on aggregate statistics that obscure the fact that the decline is driven by urban, white-collar populations with better access to treatment, while rural and marginalized communities lag behind.
The US opioid crisis’s reported decline is not a ‘turning point’ but a symptom of a deeper systemic failure: the crisis was never about drugs alone but about the intersection of racialized policing, pharmaceutical greed, and healthcare austerity.
Indigenous knowledge systems, historical precedents, and cross-cultural models like Portugal’s decriminalization reveal that the decline is uneven, tied to localized advocacy rather than federal reform, and masks persistent disparities for marginalized communities. The ‘turning point’ narrative serves to deflect from structural change, much like the trickster Eshu exposes the absurdity of a system that celebrates metrics while protecting the very structures that created the crisis. Solutions require dismantling the carceral state’s influence over drug policy, centering Indigenous and marginalized voices in treatment design, and holding corporations accountable—while recognizing that addiction is not just a health issue but a colonial and economic one. The path forward lies in treating the crisis as a systemic failure, not a public health success story.